Publications

Study Phase 3 Of Lenalidomide (Len) In Patients (Ptes) With Myelodysplastic Syndrome (Smd) Without Del(5Q) Of Low Risk And With Transfusional Dependence (Dt), Refractories Or Non Responsive To Stimulating Agents Of Erythropoiesis

AuthID
P-00J-YBT

Author(s)

Del Canizo, MC

Almeida, A

Giagounidis, A

Fenaux, P

Santini, V

Ozawa, K

Document Type

Abstract

Year published

2015

Published

in HAEMATOLOGICA, ISSN: 0390-6078

Volume: 100, Pages: 149-149 (1)

Conference

57Th National Congress of the Spanish-Society-Of-Hematology-And-Hemotherapy, Date: OCT 22-24, 2015, Location: Valencia, SPAIN, Sponsors: Spanish Soc Hematol & Hemotherapy, Novartis Oncol, Celgene, Takeda Oncol, Bristol Myers Squibb, Janssen, Amgen Oncol, Roche, Gilead, GlaxoSmithKline, Alexion, Ariad

Indexing